Faldaprevir: Phase IIa started

Trek began an open-label, international Phase IIa trial to evaluate once-daily 120 mg oral TD-6450 plus 120 mg oral faldaprevir with and without ribavirin for 12 weeks in 25 patients. Trek has exclus...